Therapeutic monoclonal antibodies

Taketo Yamada

Research output: Contribution to journalReview articlepeer-review

45 Citations (Scopus)


Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs). In the 35 years since the first process for creating MoAbs was introduced, they have remained the centerpiece of the growing biotechnology and pharmaceutical industry. Herein, I review the history, development, and clinical settings of therapeutic MoAbs that have had a significant impact on life-saving medicine.

Original languageEnglish
Pages (from-to)37-46
Number of pages10
JournalKeio Journal of Medicine
Issue number2
Publication statusPublished - 2011 Jun


  • Immunoglobulin
  • Molecular target therapy
  • Monoclonal antibody

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Therapeutic monoclonal antibodies'. Together they form a unique fingerprint.

Cite this